This week’s edition of InnovationRx delves into the medical community’s critical responses to President Trump’s claims regarding Tylenol, a startup revolutionizing drug pricing, Pfizer’s latest venture into obesity treatments, and much more. To receive the newsletter directly in your inbox, subscribe here.
AFP via Getty Images
Recently, at a press briefing, President Donald Trump asserted that acetaminophen, the active ingredient in Tylenol, could lead to autism in children if consumed during pregnancy. He also perpetuated the debunked notion that the current childhood vaccination schedule triggers autism. In light of these remarks, the Department of Health and Human Services announced that the FDA would begin revising the safety label for acetaminophen.
Kenvue, the maker of Tylenol, strongly refuted Trump’s claims in a statement, asserting that “independent, credible science unequivocally demonstrates that acetaminophen does not cause autism.”
Medical organizations echoed this defense. The American Academy of Pediatrics declared that “the White House’s presentation on autism was filled with misleading claims and dangerous misinformation.” The World Health Organization observed that numerous studies over the previous decade have shown “no consistent link” between the medication and autism. Furthermore, the American College of Obstetricians and Gynecologists reiterated the drug’s safety, cautioning that “the conditions for which individuals utilize acetaminophen during pregnancy pose significantly greater risks than any speculative threats.”
Notably, despite this backlash, a Forbes inquiry revealed that Trump’s statements are going viral on TikTok, amassing over 100 million views shortly after the conference, according to analytics firm Zelf. The popularity of videos featuring Trump’s accusations surged, despite the platform’s policies which prohibit “health information that could cause significant harm.”
Quatiba Davis, the chief clinical officer of ABA Centers, emphasized that such discussions distract from the pressing need for enhanced care accessibility for individuals with autism. “Autism is a lifelong condition, effectively managed with compassionate, comprehensive therapy plans,” she stated, adding, “Our primary focus must be on eliminating waitlists and bureaucratic hurdles faced by individuals seeking autism diagnosis or services in the United States.”
This Startup Achieves a $3.25 Billion Valuation by Transforming Drug Pricing Software
Founders Ryan Kelly and AJ Loiacono of Judi Health
Judi Health
AJ Loiacono recognized a notable success after implementing his medical benefits administration software within his own company, enabling a significant cost savings of 11% annually for 1,800 health plan members, including employees and their families. Moreover, the processing time for claims substantially decreased from over six months to a mere 18 days. Remarkably, these savings were achieved while simultaneously enhancing employee benefits.
“We streamlined costs per member per month by eliminating excessive fees and encumbrances on the plan,” Loiacono told Forbes.
Following this successful trial, Loiacono’s initial firm, known for its work in pharmacy benefits as Capital Rx, has since transformed into Judi Health, focusing on medical claims administration for businesses and third-party administrators. The company recently secured $252 million in equity funding, spearheaded by Wellington Management and General Catalyst, bringing its total funding to an impressive $607 million and elevating its market valuation to $3.25 billion — more than double its previous $1.5 billion valuation in March 2024. Notable investors include Goldman Sachs Asset Management and Generation Investment Management, chaired by former Vice President Al Gore. The funding was so oversubscribed that eager investors also acquired over $150 million worth of stakes from the company’s initial backers.
The separation between medical benefits and prescription ones often leads to redundancy, increased costs, and dissatisfaction among doctors and patients. The convoluted drug pricing landscape—laden with rebates, clawbacks, and multiple fees—complicates the situation further. To combat this, Loiacono designed modular, cloud-based software named Judi (short for “adjudicate,” reflecting its function in claims processing) to provide a clearer, more affordable approach to the entire process. As employers seek greater control over escalating drug costs, Judi has established a robust pharmacy benefit management segment, anticipating revenue of $3.7 billion this year, marking a 75% increase from the prior year’s figure of $2.1 billion. The company’s technology manages claims administration without incurring the financial risks associated with those claims, similar to Fidelity’s management of 401(k) plans.
“AJ is someone who has been dedicated to tackling this issue for a long time,” noted Jonah Surkes, an investor with Generation. “This industry is incredibly complex, with numerous vocal entities that have maneuvered aggressively to consolidate market dominance. AJ has exhibited remarkable perseverance throughout this process.”
Read the full story at Forbes.
BIOTECH AND PHARMA
Pharmaceutical titan Pfizer is poised to acquire Metsera, a biotech company specializing in obesity treatments, in a deal potentially valued at up to $7.3 billion. Metsera is advancing several obesity pharmaceuticals, including one aimed to rival Wegovy or Zepbound, potentially requiring injections as infrequently as once a month. The company is also working on oral formulations of these medications, currently in clinical trials. Earlier in the year, Pfizer halted development of its own anti-obesity drug, danuglipron, due to complications involving liver injuries detected during trials.
Plus: The FDA has greenlit a subcutaneous version of Merck’s acclaimed cancer therapy, Keytruda, previously only available via intravenous administration. This new format aims to enhance treatment flexibility for healthcare providers and is expected to augment patient access to critical therapies.
DIGITAL HEALTH AND AI
Pi Health, a Massachusetts-based startup, has partnered with pharmaceutical giant GSK for a global Phase 2 clinical trial on an experimental cancer drug. Utilizing its AI-driven software, Pi Health will recruit participants for the trial and oversee site selection, regulatory submissions, and additional components of the operation on behalf of GSK. Forbes previously examined the contributions of Pi Health’s founders earlier this year.
PUBLIC HEALTH AND HOSPITALS
According to a recent Experian report, over 40% of healthcare providers claim that more than 10% of their insurance claims are denied. The primary reason cited for these denials is missing or incorrect data. Nearly two-thirds (68%) of respondents indicated that submitting data-free claims has become more challenging compared to a year ago. The fragmented nature of data retrieval is a significant issue, with 81% of providers utilizing multiple systems for patient check-in and information collection. Staffing also poses a challenge, as 43% of providers admitted to being understaffed concerning claim submissions.
Plus: Health authorities report that measles outbreaks are occurring in Utah and Arizona, primarily affecting unvaccinated children.
WHAT WE’RE READING
Since the introduction of RSV vaccines for expectant mothers and antibodies for infants in 2023, hospitalizations for respiratory disease among infants have decreased by half.
A ProPublica investigation revealed that over the past 15 years, more than 90 psychiatric facilities have violated federal regulations in patient care, yet have faced minimal repercussions.
Lilly disclosed on Tuesday its plans to construct a $6.5 billion facility in Houston dedicated to the production of its oral GLP-1 medication, orforglipron. The company aims to submit an application for FDA approval of the medication by year-end.
Federal and state budget cuts are jeopardizing initiatives designed to train and retain doctors in rural California.
The Democratic Republic of Congo is currently grappling with a particularly severe Ebola outbreak, reporting 47 cases and 25 confirmed deaths to date.
A federal district court ruled that the National Institutes of Health must reinstate unlawfully terminated research grants to scientists from the University of California system.
MORE FROM FORBES
ForbesTrump Is Slashing Grad School Loans. These Companies Are Scrambling To Step InBy Danielle ChemtobForbesHow The Raising Cane’s Founder Built A $22 Billion Chicken Finger Empire That’s Snoop Dogg’s Favorite Fast-Food ChainBy Chase Peterson-WithornForbesTesla’s Full-Self Driving Software Is A Mess. Should It Be Legal?By Alan Ohnsman
